If approved, Dupixent would be the first medicine available in the U.S. indicated to treat eosinophilic esophagitis
There are approximately 160,000 patients in the U.S. living with eosinophilic. | April 4, 2022
/PRNewswire/ Dupixent significantly reduced itch at 12 weeks, and at 24 weeks nearly three times as many Dupixent patients experienced clinically meaningful.
/PRNewswire/ Dupixent 300 mg weekly is the only biologic medicine to show positive, clinically meaningful Phase 3 results in adults and adolescents with.
/PRNewswire/ Dupixent 300 mg weekly is the only biologic medicine to show positive, clinically meaningful Phase 3 results in adults and adolescents with.